HEC Pharma (1558 HK): Robust 1H23 Performance on Flu Outbreak in China
426 Views02 Oct 2023 21:57
SUMMARY
- Yichang HEC Changjiang Pharma (1558 HK) reported a whopping 148% YoY growth in revenue to RMB3,209M in 1H23. Net profit rebounded to RMB3,209M from a loss of RMB33M in 1H22.
- In H1 2023, revenue from Kewei, approved for first-line treatment of influenza, jumped 186% YoY to RMB2,881M, representing ~90% of total revenue, mainly due to spiking flu cases in China.
- Recently, the company obtained approval for premixed Protamine human insulin injection and submitted marketing application for its self-developed product, Yiqibuvir for the treatment of chronic Hepatitis C in China.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- HEC Pharma (1558 HK): Strong Performance to Continue as Flu Activity Is On Rise In China04 Jan 2024
- HEC Pharma (1558 HK): Robust 1H23 Performance on Flu Outbreak in China02 Oct 2023
- HEC Pharma (1558 HK): Core Product Saw Volume Recovery in 1H 2022; New Launches to Accelerate Growth27 Nov 2022
- Yichang HEC Changjiang Pharma (1558 HK): Multiple New Products Launches Bring New Opportunities24 Nov 2021
x